Severe & Moderate BPH Symptoms in Mid-Aged Men Improve with Isoflavonoid-Equol Treatment: Pilot Intervention Study

Edwin D. Lephart

The Department of Physiology and Developmental Biology, Brigham Young University, Provo, USA.

DOI: 10.4236/oju.2013.31004                

Abstract

Benign prostatic hyperplasia (BPH) is the pathological cellular progression of glandular proliferation associated with aging. Current available treatment options for BPH have limitations and various adverse effects. Equol is a polyphenolic/isoflavonoid molecule derived from intestinal metabolism, dairy and dietary plant sources. It has the unique characteristic to bind specifically 5α-dihydrotestosterone (5α-DHT) by sequestering 5α-DHT from the androgen receptor, thus decreasing androgen hormone actions to improve prostate health by acting as a selective androgen modulator (SAM). It also has affinity for estrogen related receptor gamma (ERR-γ) and estrogen receptor beta (ER-β) within the prostate that is known to improve male health via selective estrogen receptor modulatory (SERM) activities to decrease inflammation, cellular proliferation and carcinogenesis. We investigated the possible clinical efficacy of equol on the symptoms associated with benign prostatic hyperplasia (BPH) in this study. Materials and Methods: We performed a pilot intervention study evaluating the effects of low dose oral equol supplement (6 mg, twice a day with meals) for 4 weeks in a total of 18 men (49 - 60 years old) with moderate or severe BPH. Subjects included in the study: gave informed consent, underwent a physical examination and verified their BPH symptoms as measured by the International Prostate Symptom Scores (IPSS) and then were assigned to the moderate or severe BPH groups based upon their total IPSS index. All adverse events were reported. The primary efficacy measure was the IPSS parameters comparing baseline to 2 and 4 week IPSS indices. Blood samples were collected at the baseline and 4th week visits that served as secondary efficacy parameters that included testosterone, 5α-DHT and general blood chemistries along with cardiac and hepatic function panels. Results: Low dose equol positively improved moderate to severe BPH symptoms according to the IPSS indices. In moderately symptomatic men (n = 10) 5 out of 7 of the IPSS parameters significantly improved by 4 weeks of equol treatment. In severely symptomatic men (n = 8) all 7 of the IPSS parameters significantly improved with 4 weeks of equol treatment. There were no significant changes in androgen levels, general blood chemistries or cardiac and hepatic function parameters. Although, 5α-DHT levels declined by 21% in severely symptomatic men (from baseline vs. 4 week values). Conclusion: These findings suggest that equol may provide a well tolerated and rapid beneficial therapy for BPH that can be used alone or in combination with current pharmaceutical therapies. The beneficial clinical efficacy of equol observed in this study may be due to the multiple positive biological actions that are not present in current pharmaceutical treatments.

Keywords

Isoflavonoid; Equol; BPH; Androgens; SERM

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	J. T. Wei, E. A. Calhoun and S. J. Jacobsen, “Benign Prostatic Hyperplasia,” In: M. S. Litwin and C. S. Saigal, Eds., Urologic Disease in America, US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, US Government Publishing Office, Washington, 2004, pp. 43-69.
[2]	A. Gravas and M. Oelke, “Current Status of 5α-Reductase Inhibitors in the Management of Lower Urinary Tract Symptoms and BPH,” World Journal of Urology, Vol. 28, No. 1, 2010, pp. 9-15. doi:10.1007/s00345-009-0493-y
[3]	T. Fujimura, S. Takahashi, T. Urano, et al., “Differential Expression of Estrogen-Related Receptors Beta and Gamma (ERRbeta and ERRgamma) and Their Clinical Significance in Human Prostate Cancer,” Cancer Science, Vol. 101, No. 3, 2010, pp. 646-651. doi:10.1111/j.1349-7006.2009.01451.x
[4]	S. J. Ellem and G. P. Risbridger, “The Dual, Opposing Role of Estrogens in the Prostate,” Annals New York Academy of Science, Vol. 1155, No. 1, 2009, pp. 174-186. doi:10.1111/j.1749-6632.2009.04360.x
[5]	S. J. Berry, D. S. Coffey, P. C. Walsh, et al., “The Development of Human Benign Prostatic Hyperplasia with Age,” Journal of Urology, Vol. 132, No. 3, 1984, pp. 474-479.
[6]	J. T. Wei, E. Calhoun and S. J. Jacobsen, “Urologic Diseases in America Project: Benign Prostatic Hyperplasia,” Journal of Urology, Vol. 179, No. 5, 2008, pp. S75-S80. doi:10.1016/j.juro.2008.03.141
[7]	M. Emberton, N. Zinner, M. C. Michel, et al., “Managing the Progression of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Therapeutic Options for the Man at Risk,” British Journal of Urology, Vol. 100, No. 2, 2007, pp. 249-253. doi:10.1111/j.1464-410X.2007.07056.x
[8]	M. J. Barry and C. G. Roehrborn, “Benign Prostatic Hyperplasia,” British Medical Journal, Vol. 323, No. 7320, 2001, pp. 1042-1046. doi:10.1136/bmj.323.7320.1042
[9]	H. Adlercreutz and W. Mazur, “Phyto-Estrogens and Western Diseases,” Annuals of Medicine, Vol. 29, No. 2, 1997, pp. 95-120.
[10]	K, Griffiths, L. Denis, A. Turkes, et al., “Phytoestrogens and Diseases of the Prostate Gland,” Baillieres Clinical Endocrinology Metabolism, Vol. 12, No. 4, 1998, pp. 625-647. doi:10.1016/S0950-351X(98)80008-6
[11]	C. Brossner, K. Petritsch, K. Fink, et al., “Phytoestrogen Tissue Levels in Benign Prostatic Hyperplasia and Prostate Cancer and Their Association with Prostate Diseases,” Urology, Vol. 64, No. 4, 2004, pp. 707-711. doi:10.1016/j.urology.2004.04.046
[12]	V. U. Kumar, “Phyto-Oestrogens and Prostatic Growth,” National Medical Journal of India, Vol. 17, No. 1, 2004, pp. 22-26.
[13]	A. Domenica, B. Alessandra, F. Polito, et al., “The Combination of Serenoa Repens, Selenium and Lycopene Is More Effective than Serenoa Repens Alone to Prevent Hormone Dependent Prostatic Growth,” Journal of Urology, Vol. 186, No. 4, 2011, pp. 1524-1529. doi:10.1016/j.juro.2011.05.049
[14]	G. S. Gerber, “Saw Palmetto for the Treatment of Men with Lower Urinary Tract Symptoms,” Journal of Urology, Vol. 163, No. 5, 2000, pp. 1408-1412. doi:10.1016/S0022-5347(05)67631-8
[15]	A. C. Buck, “Is There a Scientific Basis for the Therapeutic Effects of Serenoa Repens in Benign Prostatic Hyperplasia? Mechanism of Action,” Journal of Urology, Vol. 172, No. 5, 2004, pp. 1792-1799. doi:10.1097/01.ju.0000140503.11467.8e
[16]	C. Manach, G. Williamson, C. Morand, et al., “Bioavailability and Bioefficacy of Polyphenols in Humans. I Review of 97 Bioavailability Studies,” American Journal of Clinical Nutrition, Vol. 81, No. 1, 2005, pp. 230S-242S.
[17]	J. M. Smoliga, J. A. Baur and H. A. Hausenblas, “Resveratrol and Health-A Comprehensive Review of Human Clinical Trials,” Molecular Nutrition Food Research, Vol. 55, No. 8, 2011, pp. 1129-1141. doi:10.1002/mnfr.201100143
[18]	K. D. Setchell and C. Clerici, “Equol: History, Chemistry, and Formation,” Journal of Nutrition, Vol. 140, No. 7, 2010, pp. 1355S-1362S. doi:10.3945/jn.109.119776
[19]	K. D. R. Setchell, C. Clerici, E. D. Lephart, et al., “S-Equol, a Potent Ligand for Estrogen Receptor β, Is the Exclusive Enantiomeric Form of the Soy Isoflavone Metabolite Produced by Human Intestinal Bacterial Flora,” American Journal of Clinical Nutrition, Vol. 81, No. 5, 2005, pp. 1072-1079.
[20]	C. L. Frankenfeld, “Dairy Consumption Is a Significant Correlate of Urinary Equol Concentration in a Representative Sample of US Adults,” American Journal of Clinical Nutrition, Vol. 93, No. 5, 2011, pp. 1109-1116. doi:10.3945/ajcn.111.011825
[21]	N. Hounsome, B. Grail, A Tomos, et al., “High-Throughput Antioxidant Profiling in Vegetables by Fourier-Transform Ion Cyclotron Resonance Mass Spectrometry,” Functional Plant Science & Biotechnology, Vol. 4, No. 1, 2010, pp. 1-10.
[22]	A. Hjer, S. Alder, S. Purup, et al., “Effects of Feeding Dairy Cows Different-Legume-Grass Silages on Milk Phytoestrogen Concentration,” Journal of Dairy Science, Vol. 95, No. 8, 2012, pp. 4526-4540.
[23]	E. D. Lephart, “Isoflavones and Prenatal Exposure to Equol,” In: V. R. Preedy, Ed., Isoflavones: Chemistry, Analysis, Function and Effects, The Royal Society of Chemistry, Thomas Graham House, Cambridge, 2013, pp. 480-499.
[24]	T. D. Lund, D. J. Munson, M. E. Hadly, et al., “Equol Is a Novel Anti-Androgen That Inhibits Prostate Growth and Hormone Feedback,” Biology of Reproduction, Vol. 70, No. 4, 2004, pp. 1188-1195. doi:10.1095/biolreprod.103.023713
[25]	T. D. Lund, C. Blake, L. Bu, et al., “Equol an Isoflavonoid: Potential for Improved Prostate Health, in Vitro and in Vivo Evidence,” Reproductive Biology & Endocrinology, Vol. 9, No. 4, 2011, pp. 1-9. doi:10.1186/1477-7827-9-4
[26]	J. Hirvonen, A. M. Rajalin, G. Wohlfahrt, et al., “Transcriptional Activity of Estrogen-Related Receptor Gamma (ERRgamma) is Stimulated by the Phytoestrogen Equol,” Journal of Steriod Biochemistry & Molecular Biology, Vol. 123, No. 1-2, 2011, pp. 46-57. doi:10.1016/j.jsbmb.2010.11.001
[27]	R. Gopaul, H. E. Knaggs and E. D. Lephart, “Biochemical Investigation and Gene Analysis of Equol: A Plant and Soy-Derived Isoflavonoid with Anti-Aging and Antioxidant Properties with Potential Human Skin Applications,” Biofactors, Vol. 38, No. 1, 2012, pp. 44-52. doi:10.1002/biof.191
[28]	J. M. Hamilton-Reeves, S. A. Rebello, W. Thomas, et al., “Isoflavone-Rich Soy Protein Isolate Suppresses Androgen Receptor Expression without Altering Estrogen Receptor-β Expression or Serum Hormonal Profiles in Men at High Risk of Prostate Cancer,” Journal of Nutrition, Vol. 137, No. 7, 2007, pp. 1769-1775.
[29]	C. D. Gardner, B. Oelrich, J. P. Liu, et al., “Prostatic Soy Isoflavone Concentrations Exceed Serum Levels after Dietary Supplementation,” Prostate, Vol. 69, No. 7, 2009, pp. 719-726. doi:10.1002/pros.20922
[30]	T. E. Hedlund, P. D. Maroni, P. G. Ferucci, et al., “Long-Term Dietary Habits Affect Soy Isoflavone Metabolism and Accumulation in Prostatic Fluid in Caucasian Men,” Journal of Nutrition, Vol. 135, No. 6, 2005, pp. 1400-1406.
[31]	H. Akaza, N. Miyanaga, N. Takashima, et al., “Comparisons of Percent Equol Producers between Prostate Cancer Patients and Controls: Case-Controlled Studies of Isoflavones in Japanese, Korean and American residents,” Japan Journal of Clinical Oncology, Vol. 34, No. 2, 2004, pp. 86-89. doi:10.1093/jjco/hyh015
[32]	P. J. Magee, M. Raschke, C. Steiner, et al., “Equol: A Comparison of the Effects of the Racemic Compound with That of the Purified S-Enantiomer on the Growth, Invasion, and DNA Integrity of Breast and Prostate Cells in Vitro,” Nutrition and Cancer, Vol. 54, No. 2, 2006, pp. 232-242. doi:10.1207/s15327914nc5402_10
[33]	M. Tanaka, K. Fujimoto, Y. Chihara, et al., “Isoflavone Supplements Stimulated the Production of Serum Equol and Decreased the Serum Dihydrotestosterone Levels in Healthy Male Volunteers,” Prostate Cancer and Prostatic Disease, Vol. 12, No. 3, 2009, pp. 247-252. doi:10.1038/pcan.2009.10